JMP Securities Initiates Coverage On Foghorn Therapeutics with Market Outperform Rating, Announces Price Target of $9
Author: Benzinga Newsdesk | April 23, 2025 06:36am
JMP Securities analyst Silvan Tuerkcan initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Market Outperform rating and announces Price Target of $9.